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Downregulation of leucine-rich 
repeat-containing 8a limits 
Proliferation and increases 
sensitivity of glioblastoma to 
Temozolomide and carmustine
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and Alexander A. Mongin2*
1 Department of Neurosurgery, Albany Medical Center, Albany, NY, United States, 2 Department of Neuroscience and 
Experimental Therapeutics, Albany Medical College, Albany, NY, United States, 3 Section for Cell Biology and Physiology, 
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Background: Glioblastoma (GBM) is the most common primary malignant brain tumor in 
adults. Ubiquitously expressed volume-regulated anion channels (VRAC) are thought to 
play a role in cell proliferation, migration, and apoptosis. VRAC are heteromeric channel 
complexes assembled from proteins belonging to the leucine-rich repeat-containing 8A 
(LRRC8A through E), among which LRRC8A plays an indispensable role. In the present 
work, we used an RNAi approach to test potential significance of VRAC and LRRC8A in 
GBM survival and sensitivity to chemotherapeutic agents.
Methods: Primary GBM cells were derived from a human surgical tissue sample. LRRC8A 
expression was determined with quantitative RT-PCR and downregulated using siRNA. 
The effects of LRRC8A knockdown on GBM cell viability, proliferation, and sensitivity to 
chemotherapeutic agents were determined using 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl 
tetrazolium bromide and Coulter counter assays. Cell cycle progression was further explored 
using fluorescence-activated cell sorting analysis of propidium iodide-stained cells.
results: Temozolomide (TMZ), carmustine, and cisplatin reduced GBM cell survival with 
the IC50 values of ~1,250, 320, and 30 µM, respectively. Two of three tested gene-specific 
siRNA constructs, siLRRC8A_3 and siLRRC8A_6, downregulated LRRC8A expression 
by >80% and significantly reduced GBM cell numbers. The most potent siLRRC8A_3 
itself reduced viable cell numbers by ≥50%, and significantly increased toxicity of the 
sub-IC50 concentrations of TMZ (570  µM) and carmustine (167  µM). In contrast, the 
effects of siLRRC8A_3 and cisplatin (32  µM) were not additive, most likely because 
cisplatin uptake is VRAC-dependent. The results obtained in primary GBM cells were 
qualitatively recapitulated in U251 human GBM cell line.
conclusion: Downregulation of LRRC8A expression reduces GBM cell proliferation and 
increases sensitivity to the clinically used TMZ and carmustine. These findings indicate 
that VRAC represents a potential target for the treatment of GBM, alone or in combina-
tion with the current standard-of-care.
Keywords: glioblastoma, leucine-rich repeat-containing 8a, volume-regulated anion channel, temozolomide, 
carmustine, cisplatin
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inTrODUcTiOn
Glioblastoma (GBM) is the most common malignant primary 
brain tumor in adults (1, 2), with an annual incidence of approxi-
mately 4 per 100,000 people and 14,000 new diagnoses per year 
(3). Despite extensive translational work and clinical studies, 
the prognosis for GBM patients remains grim. Newly diagnosed 
patients typically receive maximal safe surgical resection, fol-
lowed by treatment with the chemotherapeutic temozolomide 
(TMZ) and radiation therapy (2). However, even after receiving 
this standard-of-care treatment, median relative survival time 
ranges from 13 to 15 months only, with a 2-year overall survival 
of 21–26% (3, 4).
Temozolomide is the most commonly used chemotherapeutic 
in the treatment of GBM. It is an imidazotetrazine compound 
that is metabolically converted to the reactive methyldiazonium 
cation, which in turn methylates DNA and triggers apoptotic 
cell death (5, 6). GBM tumor cells develop chemoresistance by 
upregulating methylguanine methyltransferase to remove the 
cytotoxic O6-methylguanine, or via selection of mismatch repair-
deficient cells, which can tolerate alkylating agents (5). Additional 
adjuvant therapy involves the surgical implantation of Gliadel 
wafers, which provide local delivery of the chemotherapeutic 
polymer carmustine (bis-chloroethylnitrosourea) (7, 8). Gliadel 
wafers are used less frequently because systematic review of clini-
cal data indicates that they only increase survival marginally and 
are associated with high-complication rates (9). Limited efficacy 
of existing therapies creates an urgent need for development of 
novel treatment modalities.
Ion channels are frequently discussed as possible targets 
for cancer treatment due to their many roles in tumor biology 
[reviewed in Ref. (10–12)]. In the present study, we focused on 
the ubiquitously expressed volume-regulated chloride/anion 
channels (VRAC). VRAC were first functionally discovered 
in epithelial and immune cells (13, 14), and soon thereafter 
detected in numerous other cell types, including rat glioma cells 
(15–19). Although the primary function of VRAC is cell volume 
regulation, these channels are believed to play a role in cell 
proliferation, migration, and apoptosis, in normal and malignant 
cells [reviewed in Ref. (17, 19–21)]. Due to their purported sig-
nificance in proliferation and migration, VRAC have long been 
considered a potential therapeutic target. However, the direct 
evidence for their contribution to these processes has been lack-
ing due to limited specificity of pharmacological VRAC blockers, 
and because the molecular identity of VRAC remained elusive for 
nearly three decades (19).
In 2014, two groups independently identified proteins of the 
leucine-rich repeat-containing 8A (LRRC8A) as components 
of the heteromeric VRAC (22, 23). LRRC8A is mandatory for 
VRAC activity but this subunit has to be heteromerized with 
at least one additional protein from the same LRRC8 family to 
produce a functional, presumably hexameric channel complex 
(23). Our laboratory was the first to establish the indispensable 
Abbreviations: DPBS, Dulbecco’s phosphate-buffered saline; FBS, fetal bovine 
serum; LRRC8A, leucine-rich repeat-containing 8A; MEM, minimal essential 
medium; VRAC, volume-regulated anion channels.
role of LRRC8A in forming VRAC in rat astrocytes (24), and we 
subsequently found that in astroglial cells there are at least two 
functionally distinct LRRC8A-containing VRAC heteromers 
(25). As GBM tumors are thought to originate from anaplastic 
astroglia or glial progenitor cells (26, 27), the prior work prompted 
us to test if the LRRC8-containing channels are important for 
GBM cell proliferation. Furthermore, we explored whether tar-
geting VRAC could interfere with the effect of the clinically used 
chemotherapeutic agents, TMZ, and carmustine. Given the prior 
findings that the LRRC8A/LRRC8D-containing VRAC facilitate 
cisplatin sensitivity in several cell types (28, 29), we used cisplatin 
as a reference compound.
MaTerials anD MeThODs
Materials and reagents
Temozolomide, carmustine, and 3-(4,5-dimethylthiazol-2-yl)-
2,5-diphenyl tetrazolium bromide (MTT) were purchased from 
Millipore-Sigma (St. Louis, MO, USA). Cisplatin was acquired 
from Tocris/Bio-Techne (Minneapolis, MN, USA). Lipofectamine 
RNAiMax, DNase-free RNase A, and 1 mg/ml stock solution of 
propidium iodide in water were from Thermo Fisher Scientific 
(Waltham, MA, USA). Cell culture components—fetal bovine 
serum (FBS), glutamine-containing Earl’s minimal essential 
medium (MEM, cat. # 10,293), OptiMEM, penicillin plus strep-
tomycin, and the recombinant protease TrypLE Express, all of the 
Gibco brand—were from Thermo Fisher Scientific. Quantitative 
PCR primers for LRRC8A and the housekeeping genes RPL13a, 
RPS20, and GAPDH, gene-specific siRNAs and negative control 
Allstars siRNA were all purchased from Qiagen (Germantown, 
MD, USA). All other salts and reagents were purchased from 
Millipore-Sigma, and were of analytical grade, unless specified 
otherwise.
Carmustine and TMZ were dissolved under sterile conditions 
in dimethyl sulfoxide (DMSO) to stock concentrations of 30 and 
150 mM, respectively, and stored at −20°C until used in experi-
ments. Cisplatin was dissolved in sterile Dulbecco’s phosphate-
buffered saline (DPBS) to produce 3.3 mM stock solution, and 
stored at −20°C until used.
Primary culture of gBM and U251  
Mg cell line
Primary GBM cells, which had been characterized in our prior 
work, were prepared from a surgical GBM tissue sample as 
previously described (30). The specimen was obtained under the 
protocol approved by the Albany Medical Center Institutional 
Review Board, with written patient consent. The GBM origin 
of tissue was histologically confirmed by a pathologist at 
the time of resection. Briefly, tumor tissue was washed with 
ice-cold Ca2+/Mg2+-free phosphate-buffered saline (PBS, pH 
7.4), dissected into small pieces, digested in the solution of 
0.125% trypsin/0.015% EDTA, which additionally contained 
DNAse I, and further gently dissociated using trituration with 
a fire-polished glass Pasteur pipette. The dissociated cells were 
initially propagated in T75 cell culture flasks in DMEM plus 
20% FBS supplemented with 100 U/ml penicillin, and 100 µg/ml 
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streptomycin. After two passages, the FBS content was reduced 
to 10%, and penicillin and streptomycin concentrations were 
reduced to 50 U/ml and 50 µg/ml, respectively. Propagated cells 
were removed from the substrate using recombinant protease 
TrypLE, transferred into freezing medium, and stored in liquid 
nitrogen.
For the presented work, GBM  cells were re-plated in MEM 
supplemented with 10% FBS, 50 µg/ml penicillin, and 50 µM strep-
tomycin, and grown in T75 flasks in the humidified atmosphere 
of 5% CO2/balance air at 37°C. Cells were periodically passaged 
after they reached 70–90% confluence, or used for experimental 
procedures as described below. All presented experiments were 
carried out with cells in passages 3 through 13.
For comparative purposes, we used human GBM cell line U251 
MG (hereafter referred to as U251). This cell line is originally 
derived in the early 1970s from a male patient with malignant 
grade III–IV astrocytoma (31). U251 utilized in this study was 
a gift of Dr. Michael G. Kaplitt. The initial passage of these cells 
is unknown. Among other features, U251 express a mutated p53 
protein, which is typical for GBM tumors, and they are positive 
for the astroglial cell marker, glial fibrillary acidic protein (GFAP) 
(32). Expression of human cell markers and GFAP immunoreac-
tivity has been confirmed in our prior published work (33). U251 
cells were propagated in MEM supplemented with 10% FBS and 
antibiotics, as described above. The cultivation and assay condi-
tions were the same as for primary GBM cells.
Quantitative rT-Pcr (qrT-Pcr) analysis 
of gene expression
Relative expression of LRRC8A mRNA and the efficacy of 
siRNA gene knockdowns were determined using qRT-PCR. 
GBM cells were plated in 60-mm Petri dishes. Non-transfected 
or siRNA-transfected cells were grown for 48 h. mRNA species 
were isolated using the RNAqueous-4PCR kit (Thermo Fisher 
Scientific) according to the manufacturer’s protocol. mRNA 
was converted to cDNA using the iScript cDNA synthesis kit 
(Bio-Rad Laboratories, Hercules, CA, USA). Human LRRC8A 
expression levels were determined using quantitative PCR 
primers (Qiagen cat. #QT01023302) and SYBR Green master 
mix (Bio-Rad). The expression levels were normalized within 
each sample to the housekeeping genes, the ribosomal proteins 
RPL13A (cat.# QT00089915), and RPS20 (cat.# QT01666847). 
Real-time detection of PCR products was done using a CFX96 
Real-Time PCR setup (Bio-Rad).
sirna Transfections
Glioblastoma cell transfection was performed as previously 
described (24). Briefly, primary GBM or U251 cells were plated 
in 24-well cell culture plates or 60-mm Petri dishes (10,000 
cells per well or ~150,000 cells per Petri dish) and grown for 
1 (U251) or 3 days (primary GBM) prior to transfection. The 
cell culture medium was removed and cells were washed with 
the serum-free OptiMEM, before transfection in the same 
medium with either negative control siRNA or siRNA target-
ing LRRC8A, using the Lipofectamine RNAiMax transfecting 
agent (Invitrogen/Thermo Fisher Scientific, Waltham, MA, 
USA). We used three different gene-specific siRNA constructs: 
siLRRC8A_3 (Hs_LRRC8A_3; Qiagen cat.# SI04251807), siLR-
RC8A_4 (Hs_LRRC8A_4; cat.# SI04327001), and siLRRC8A_6 
(Hs_LRRC8A_6; cat.# SI05006036), and AllStars scrambled 
siRNA as a negative control. siRNA-transfection reagent 
complexes were prepared in OptiMEM per the manufacturer’s 
instructions, and then further diluted with OptiMEM to the 
final siRNA concentration of 50  nM and added to the wells. 
After 4  h incubation with siRNA complexes, threefold excess 
of the FBS-containing cell culture medium was added on the 
top, and cells were further grown for ~44  h prior to adding 
chemotherapeutic agents. 48 h after adding chemotherapeutics 
(four full days of transfection) changes in cell proliferation and 
viability were determined using an MTT assay.
MTT assay
The MTT cell proliferation and viability assay was conducted as 
previously described (33). Briefly, GBM cells were plated into 
24-well plates at either “lower” (10,000 cells/well) or “higher” 
(40,000 cells/well) density and allowed to grow for one (U251) 
or three (primary GBM) days prior to experimental treat-
ments. Cells were subsequently treated with chemotherapeutic 
agents or transfected with siRNA as described above. After 
completing cell treatments, cell culture medium was removed 
by aspiration, and cells were washed once with the chemically 
defined basal solution containing (in millimolar): 135 NaCl, 
3.5 KCl, 1.2 MgSO4, 1.3 CaCl2, 1.2 KH2PO4, 10 HEPES, and 10 
D-glucose (pH 7.4, adjusted with NaOH). Subsequently, the 
basal medium was substituted with the same solution addition-
ally containing 0.5  mg/ml MTT. Depending on cell density, 
MTT incubation lasted 1–2 h. The MTT solution was removed 
by inverting the plate without washing. The metabolically 
formed formazan crystals were dissolved using 1 ml of acidified 
isopropanol and the absorbance of the solution in each well 
was determined at 562 nm, using a BioTek ELx800 plate reader 
(Winooski, VT, USA).
coulter counter assay
To independently verify the MTT assay results, we directly 
counted GBM and U251 cells using a Coulter counter as described 
before (33). Briefly, cells grown in 24-well plates at plating density 
as above were detached from the substrate using a recombinant 
protease TrypLE and resuspended in the ISOTON II diluent 
(Beckman Coulter, Miami, FL, USA). Cell numbers were deter-
mined using a Z2 series Coulter counter (Beckman Coulter), with 
the detection cell diameter limits set at 7–25 µm.
Flow cytometry cell cycle analysis
Cell cycle analysis was performed by quantitation of the relative 
DNA content using fluorescence-assisted cell sorting (FACS) of 
propidium iodide-stained cells as originally described by Krishan 
(34) with further extension for analysis of apoptosis (35, 36). 
Briefly, cells were plated and treated in 12-well plates as described 
for MTT assays. They were detached from the substrate with 
TrypLE, fixed for 20 min at room temperature (20°C) in a hypo-
tonic solution containing 2% paraformaldehyde, and rinsed from 
the fixative by sedimentation in PBS. Fixed cells were stained in 
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FigUre 1 | Downregulation of leucine-rich repeat-containing 8A (LRRC8A) protein limits proliferation of primary glioblastoma (GBM) cells. (a) Validation of siRNA 
constructs. GBM cells were transfected with three gene-specific siRNA constructs, siLRRC8A_3 (siA_3), siLRRC8A_4 (siA_4), or siLRRC8A_6 (siA_6). Changes in 
the LRRC8A mRNA expression levels were quantified 48 h post-transfection and normalized to the expression levels of the housekeeping gene RPL13a in the same 
samples. The data are the mean values ± SE of four independent experiments performed in triplicates (n = 4). **p < 0.01, ***p < 0.001 vs. cells transfected with 
negative control siRNA (siNC). (B) Effect of gene-specific LRRC8A siRNA on proliferation of GBM cells. Cells were transfected with LRRC8A siRNA (siA_3 or siA_6), 
or siNC. Relative proliferation rates were determined 96 h post-transfection using a 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT) assay, and 
further normalized to siNC values within the same experiment. Non-transfected cells (NTF) were used as an additional internal control. The data are the mean 
values ± SE of three independent experiments performed in triplicates (n = 3). *p < 0.05 vs. cells transfected siNC.
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the PBS solution containing 1 mg/ml DNase-free RNase A and 
10  µg/ml propidium iodide for 30  min at room temperature. 
Single cell propidium iodide fluorescence was quantified using an 
FACSCanto flow cytometer (Becton Dickinson Biosciences, San 
Jose, CA, USA) and analyzed with FlowJo 7.5 software (FlowJo, 
LLC., Ashland, OR, USA).
statistical analysis
All data are presented as the mean values ±  SEM, after nor-
malization to control values within the same experiment. 
Because of normalization, all comparisons to control values were 
performed using one-tailed t-test, followed by the Bonferroni 
post hoc correction for multiple comparisons. When applicable, 
comparisons between experimental groups were done using 
two-tailed t-test with Bonferroni post  hoc correction. Origin 
8.1 software (OriginLab, Northampton, MA, USA) was used for 
statistical analyses. A p-value of <0.05 was considered statistically 
significant.
resUlTs
LRRC8A gene expression and Validation 
of sirna Tools
In order to test functional significance of the LRRC8A-containing 
VRAC, we initially verified its expression in GBM  cells and 
validated LRRC8A-targeting siRNA constructs using quantita-
tive real-time reverse transcriptase PCR (qRT-PCR) approach. 
In the GBM cell line used in the present study, LRRC8A mRNA 
expression was 0.27 ±  0.17% when normalized to the house-
keeping gene RPL13A within the same cDNA samples (n = 5 
independent cell preparations). These values are comparable 
with those which we found in primary astroglial cells isolated 
from the rodent brain (25). We next tested three different siRNA 
constructs for their ability to knockdown LRRC8A expression. In 
order of potency, siLRRC8A_3, siLRRC8A_6, and siLRRC8A_4 
reduced the LRRC8A mRNA levels by 84% (p <  0.001), 82% 
(p < 0.01), and 73% (p < 0.001), respectively (Figure 1A). We 
further tested siLRRC8A_3 and siLRRC8A_6 for their effects 
on cell proliferation and found that siLRRC8A_3 and siLR-
RC8A_6 decreased GBM proliferation by 55% (p < 0.05) and 
21% (p < 0.05), respectively (Figure 1B). The most efficacious 
siLRRC8A_3 was used in all subsequent cell viability assays.
characterization of gBM sensitivity  
to chemotherapeutic agents
Glioblastoma cells are known to have variable sensitivity to 
chemotherapeutic agents and to develop chemoresistance 
(37–40). As we used a primary GBM cell line, we first performed 
a dose–response study to determine IC50 values for TMZ, car-
mustine, and cisplatin. We included cisplatin as an experimental 
control, because it enters cancer cells via VRAC (28, 29).
As shown in Figure  2, all three chemotherapeutic agents 
reduced viability of GBM  cells in a dose-dependent manner. 
Cisplatin showed the highest toxicity, whereas TMZ was least 
toxic. The IC50 values for cisplatin, carmustine, and TMZ, were 
approximately 30, 320, and 1,250  µM, respectively (Figure  2). 
Due to TMZ and carmustine’s hydrophobicity, their stock solu-
tions were prepared in DMSO before addition to experimental 
media. However, even in DMSO, TMZ and carmustine have a 
low solubility. Consequently, the three highest tested dosages 
of these agents were delivered with DMSO levels between 0.5 
and 1.5%. To control for vehicle toxicity, we tested the effect of 
DMSO on cell viability. DMSO alone reduced cell numbers, in a 
dose-dependent manner (Figure S1 in Supplementary Material). 
These findings are consistent with the prior reports that in some 
cell types proliferation can be inhibited by DMSO levels as low 
as 0.1% (41, 42). To reduce DMSO toxicity, further individual 
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temozolomide (TMZ), carmustine [bis-chloroethylnitrosourea (BCNU)], and 
cisplatin on viability of primary glioblastoma (GBM) cells. GBM cells were 
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cell numbers were compared 48 h later using a 3-(4,5-dimethylthiazol-2-yl)-
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LRRC8A Knockdown Decreases gBM 
Proliferation and increases sensitivity to 
TMZ and carmustine, but not cisplatin
As illustrated in Figures 3–5, knockdown of LRRC8A consistently 
decreased GBM  cell numbers by ~50%, pointing to the likely 
importance of VRAC in GBM  cell proliferation. To explore if 
LRRC8A knockdown impacts sensitivity of GBM cells to clinically 
used chemotherapeutic agents, we tested the effects of TMZ and 
carmustine in conjunction with the LRRC8A-targeting siRNA. 
As seen in Figure 3A, downregulation of LRRC8A strongly and 
significantly reduced MTT signal by 59% (p < 0.01), while TMZ 
was less potent (27% reduction, p < 0.05). The effect of combining 
LRRC8A siRNA with TMZ approached the level of additivity of 
individual treatments (73%, p < 0.01, Figure 3A). Although the 
MTT assay fairly faithfully reflects relative cell numbers (43), 
we and others have encountered situations where formazan 
production was reduced without changes in cell viability [see, 
for example, (44)]. In order to validate MTT results, we repeated 
cell treatments and directly counted cells using a Coulter counter. 
As shown in Figure 3B, the results of electronic cell counts were 
quantitatively very similar: 49, 21, and 79% for LRRC8A siRNA 
(p < 0.01), TMZ (p < 0.05), and their combination (p < 0.001), 
respectively. These findings reaffirm the conclusions on reduced 
cell proliferation after LRRC8A knockdown, and additivity of 
siRNA and TMZ effects.
In the next series of experiments, we observed very similar 
phenomena in GBM cells treated with another clinically utilized 
chemotherapeutic, carmustine. Specifically, siRNA, carmustine, 
and their combination decreased cell viability by 47% (p < 0.05), 
22% (p < 0.05), and 64% (p < 0.05), respectively (Figure 4A). In 
the latter case, due to experimental variability there was only a 
trend for additive actions of carmustine with siRNA transfection 
(p < 0.1). In the Coulter counter experiments shown in Figure 4B, 
proliferation experiments were carried out at the sub-IC50 levels 
of TMZ (570 µM) and carmustine (167 µM) and 0.38% DMSO 
was used as a vehicle control. Cisplatin was dissolved in DPBS, 
and further tested at the IC50 concentration (32 µM). No vehicle 
control was necessary in the latter case.
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FigUre 5 | Effects of cisplatin and leucine-rich repeat-containing 8A 
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effect of cisplatin vs. siRNA or mock treatment alone. NS, not significant, 
cisplatin effects in cells treated with siNC vs. cells treated with siLRRC8A_3.
siNC siLRRC8A_3 NTF
0.0
0.2
0.4
0.6
0.8
1.0
1.2 *
¶
¶¶
R
el
at
iv
e 
ce
ll 
vi
ab
ili
ty
(n
or
m
al
iz
ed
 M
TT
 c
on
ve
rs
io
n)
  - BCNU      + BCNU
#
*
0.0
0.2
0.4
0.6
0.8
1.0 ###
¶¶¶
***
¶
**
R
el
at
iv
e 
ce
ll 
nu
m
be
rs
(n
or
m
al
iz
ed
 C
ou
lte
r c
ou
nt
s)
 - BCNU     +BCNU
siNC              siLRRC8A_3
A B
FigUre 4 | Effects of carmustine [bis-chloroethylnitrosourea (BCNU)] and leucine-rich repeat-containing 8A (LRRC8A) siRNA viability and proliferation of 
glioblastoma (GBM) cells determined using 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT) (a) or Coulter counter (B) assays. GBM cells were 
transfected with siLRRC8A_3 (siA_3) or negative control siRNA (siNC). 48 h post-transfection cells were additionally treated with 167 µM BCNU. Relative levels of 
cell proliferation were determined 48 h after addition of BCNU (96 h post-transfection with siRNA) using an MTT assay. Non-transfected cells (NTF) were used as an 
additional internal control in MTT experiments. The data are the mean values ± SE of three independent experiments performed in triplicates (n = 3) in MTT assays, 
or four independent transfections (n = 4) in Coulter counter experiments. *p < 0.05, **p < 0.01, ***p < 0.001 vs. cells transfected with siNC. ¶p < 0.05, ¶¶p < 0.01, 
¶¶¶p < 0.001, within the group effect of BCNU vs. siRNA or mock treatment alone. #p < 0.05, ###p < 0.001, BCNU effect in cells treated with siNC vs. cells treated 
with siLRRC8A_3.
6
Rubino et al. LRRC8A in GBM Proliferation and Chemosensitivity
Frontiers in Oncology | www.frontiersin.org May 2018 | Volume 8 | Article 142
the same treatments reduced cell numbers in a nearly identical 
fashion: 49% (p < 0.01), 21% (p < 0.05), and 79% (p < 0.001), for 
siRNA, carmustine, and their combination, respectively. In these 
latter assays, the additive toxicity of the LRRC8A knockdown and 
carmustine was very clear and statistically significant.
We additionally tested the chemotherapeutic agent cisplatin. 
This was important because prior work in the field established that 
the LRRC8A/LRRC8D-containing VRAC is largely responsible 
for cisplatin uptake (28, 29). In contrast to TMZ and carmustine, 
downregulation of LRRC8A eliminated sensitivity of GBM cells 
to cisplatin. The individual treatments of siRNA or cisplatin 
reduced GBM cell viability by 60% (p < 0.01) and 56% (p < 0.01), 
respectively (Figure 5). Combination of siRNA plus cisplatin did 
not produce significant additional effect, reducing cell viability by 
62% (Figure 5, p = 0.38, compared with siRNA alone; p = 0.32, 
compared with cisplatin alone).
cell cycle analysis in cells Treated With 
the lrrc8a sirna and 
chemotherapeutics
In order to gain insight into potential mechanisms responsible 
for the impact of LRRC8A downregulation on cell viability 
and proliferation, we performed FACS analysis of propidium 
iodide-stained cells (34–36). The results of these experiments 
are presented in Figure  6. LRRC8A knockdown produced 
statistically significant increases in cells undergoing the S phase 
of mitosis (~twofold increases, p < 0.05, Figure 6G). We also 
found a not-significant trend for increases in the apoptotic 
cell numbers (Figure 6E). These changes were associated with 
matching decreases in the G1/G0 cell population (Figure  6F). 
When cells were treated with a combination of siRNA and 
chemotherapeutic agents, the resulting changes were much 
more profound. Both TMZ and carmustine produced three- to 
fourfold increases in the G2/M population (Figure 6F), similar 
three- to fourfold increases in S phase cells (Figure 6G), and a 
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not significant trend of four- to sevenfold increases in apoptotic 
cell numbers (Figure 6E).
effect of the LRRC8A Knockdown on 
Viability and cell cycle Distribution of 
U251 cells
For comparative purposes, we recapitulated cell viability experi-
ments in the U251 GBM cell line. We treated U251 cells with the 
LRRC8A-targeting siRNA with or without the chemotherapeutic 
agents, 570  µM TMZ or 57  µM carmustine. As a control, cells 
were treated in the same fashion but with scrambled siRNA. As 
seen in Figure 7A, under “control” conditions (negative control 
siRNA), TMZ reduced cell viability by ~25% (p < 0.001), while 
carmustine was less effective (trend for 12% inhibition, p = 0.055, 
after Bonferroni correction). In contrast, treatment with LRRC8A 
siRNA potently reduced cell numbers by ~55% (p  <  0.001). 
When the LRRC8A siRNA was combined with TMZ or carmus-
tine, increase in inhibition of cell viability was not statistically 
significant (p =  0.118 and 0.108, respectively, after Bonferroni 
correction, but see significant additivity in Figure  7B). When 
cell viability experiments were replicated using Coulter counter 
assays, the results were qualitatively similar (Figure  7B). The 
only difference was the weaker reductions in cell viability by the 
LRRC8A siRNA, perhaps reflecting less effective knockdown of 
the LRRC8A protein.
Fluorescence-assisted cell sorting cell cycle assays in U251 
cells showed the patterns of distribution of among the three 
mitotic phases and apoptotic population, which were similar to 
the results in primary GBM. However, we found a number of 
quantitative and qualitative differences. In the control treatment 
group, we found more cells moving through S and G2/M phases, 
which likely reflects the higher proliferative potential in this cell 
line, when compared to primary GBM. An additional difference 
was the presence of polyploid cells, which had been reported 
in the previous studies [see, for example, (45)]. Although we 
identified no obvious quantitative difference between control 
and the LRRC8A siRNA-treated cells, combination of siRNA 
with chemotherapeutic agents strongly increased the S phase and 
G2/M phase populations, as well as enrichment of apoptotic cells 
(see representative graphs in Figures  7C1–4 and quantitation 
in Figures  7D1–4). There were also increases in polyploid cell 
numbers.
DiscUssiOn
The present work was instigated to explore the functional signifi-
cance of the LRRC8A-containing VRAC in human gliomas. Two 
major findings of our work are: (i) downregulation of LRRC8A 
strongly decreases numbers of GBM cells, suggesting the impor-
tance of the LRRC8A-containing VRAC for their proliferation 
02
4
6
8
10
*
siNC    siA_3   siA_3   siA_3
+TMZ   +BCNU 
*
0
20
40
60
80
***
siNC    siA_3   siA_3   siA_3
+TMZ   +BCNU 
***
0
4
8
12
**
siNC    siA_3   siA_3   siA_3
+TMZ   +BCNU 
***
0
5
10
15
20
25
***
siNC    siA_3   siA_3   siA_3
+TMZ   +BCNU 
***
0.0
0.2
0.4
0.6
0.8
1.0
###
+B
C
N
U
+B
C
N
U
+T
M
Z
siNC                          siLRRC8A_3
******
***
R
el
at
iv
e 
ce
ll 
nu
m
be
rs
(n
or
m
al
iz
ed
 M
TT
 c
on
ve
rs
io
n)
***
+T
M
Z
###
0.0
0.2
0.4
0.6
0.8
1.0
¶¶¶¶¶¶
###
*
+B
C
N
U
+B
C
N
U
+T
M
Z
siNC                          siLRRC8A_3
*****
**
R
el
at
iv
e 
ce
ll 
nu
m
be
rs
(n
or
m
al
iz
ed
 C
ou
lte
r c
ou
nt
s)
*
+T
M
Z
#
Propidium iodide fluorescence (a.u.)
E
ve
nt
 c
ou
nt
s
C
el
ls
 in
 p
op
ul
at
io
n 
(%
 to
ta
l) M-2GesahpS0G-1GsisotpopA
siNC siLRRC8A siLRRC8A siLRRC8A
UNCB+ZMT+
A
C1 C2 C3 C4
D1 D2 D3 D4
B
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and viability; (ii) downregulation of LRRC8A increases sensitiv-
ity of primary GBM cells to the clinically used chemotherapeutic 
agents TMZ and carmustine, indicating that VRAC can be 
targeted for therapeutic purposes.
Volume-regulated anion channels activity is firmly associ-
ated with the ability of cells to regulate their volume, and is 
reported to play a role in cell proliferation, migration, apop-
tosis, cell excitability, and transepithelial ion transport (17, 19, 
21, 46). However, the collective evidence for these functional 
roles was rather weak due to the unknown molecular identity 
of VRAC and limited selectivity of available pharmacological 
tools. In 2014, two breakthrough publications independently 
identified VRAC as heteromeric channels assembled from the 
proteins belonging to the LRRC8 family (22, 23). Prior to this 
discovery, the idea of VRAC involvement in cell proliferation 
was supported by two types of observations: (i) non-specific 
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VRAC inhibitors were found to strongly limit cell proliferation 
in numerous cell types, including malignant cells, and (ii) in 
dividing cells, the density of VRAC currents fluctuated depend-
ing on the cell cycle stage (47–53). We believe that the present 
work is the first study to use a gene-specific RNAi approach to 
validate the significance of LRRC8A in cell proliferation. The 
inhibitory effects of the LRRC8A knockdown were quantita-
tively similar in primary GBM cells and U251 GBM cell line. 
This was recapitulated with two different cell proliferation and 
viability assays, e.g., electronic cell counting and MTT assay. 
Changes in absolute cell numbers (Coulter counter) point to the 
reduced proliferation, but we cannot exclude other mechanisms 
(see discussion below).
The idea that VRAC activity is involved in control of cell 
proliferation is important in the context of cancer cell biology. 
The role of VRAC in proliferative control is supported by the 
prior studies utilizing pharmacological inhibitors. For example, 
VRAC blockers arrest small cell lung cancer, cervical cancer, and 
T-lymphoma cells in G0/G1 phase, based on the results of cell 
cytometry and changes in the expression levels of cyclins and 
CDK kinases (50, 53). In astroglial cells, which share cell lineage 
with GBM, the VRAC blocker DCPIB also causes G0/G1 arrest 
due to cell failure to pass the G1/S checkpoint (54). The latter 
conclusion has been derived using FACS analysis, BrdU labeling, 
and assays of cyclin D1 and CDK4 expression (54). In our 
present work, knockdown of LRRC8A caused ~twofold enrich-
ment in cells allocated in the synthesis (S) phase of mitosis, and 
quantitatively similar but not statistically significant increases 
in the apoptotic population. These data differ from prior find-
ings in astrocytes and do not provide a clear picture of the cell 
cycle arrest. The discrepancies may be explained by differences 
in cell type or treatment (siRNA vs. channel blocker). It is also 
possible that our data were skewed by the loss of cell subpopula-
tions during fixation and staining procedures. Further work is 
needed to verify these findings and directly compare the effects 
of the LRRC8A knockdowns to the actions of pharmacological 
blockers.
As downregulation of the LRRC8A expression strongly 
reduced cell GBM  cell numbers, our next important question 
was if targeting VRAC could enhance the effect of the chemo-
therapeutics, TMZ and carmustine, which are currently used 
in clinical settings. The outcome of the combined treatment 
(siRNA plus chemotherapeutics) was difficult to predict based 
on the existing knowledge in the field. Prior to discovery of 
LRRC8 proteins, development of resistance to cisplatin and 
few other chemotherapeutic agents has been associated with 
dramatic downregulation of VRAC activity and decreased 
ability of cells to regulate their volume (55–57). Recently, the 
platinum-based chemotherapeutics, cisplatin, and carboplatin 
have been found to accumulate in cancer cells via the LRRC8A/
LRRC8D-containing heteromers, which were downregulated 
with the development of chemoresistance (28, 29). An additional 
complication of knocking down LRRC8A in tumor cells, which 
is unrelated to the transport of chemotoxic substances, arises 
from the established role of VRAC in apoptosis. VRAC contrib-
utes to initial apoptotic cell volume decrease, and is required 
for progression to the later stages of apoptosis (46, 58–61). 
Keeping these caveats in mind, we explored if LRRC8A knock-
down would lead to undesirable chemoresistance or apoptotic 
resistance in GBM cells. Fortunately, we did not find that to be 
the case. Downregulation of LRRC8A expression in primary 
GBM cells produced additive toxic effects with TMZ and car-
mustine. In FACS assays, combinatory treatment with siRNA 
and chemotherapeutics consistently increased cell numbers 
in S and G2/M phases of mitosis, consistent with well-known 
G2/M arrest caused by TMZ and carmustine (62, 63), but also 
significant increases in numbers of apoptotic cells.
To ensure that our observations in the primary GBM  cell 
culture are broadly applicable to other types of GBM  cells, we 
evaluated the effects of LRRC8A knockdown on the viability of 
the human U251 cells, one of the most widely used GBM cell lines. 
Much like in the primary GBM cultures, knockdown of LRRC8A 
reduced U251 cell numbers by >50% and was significantly more 
potent than treatment with either TMZ or carmustine alone. 
When we combined the LRRC8A siRNA with chemotherapeu-
tics, our assays again showed a strong trend for additivity in 
the toxic effects of both treatments, and were far superior to 
the chemotherapeutics alone. Combinatory treatment facilitated 
G2/M arrest of GBM cells and was associated with an increase 
in apoptotic cell numbers. Therefore, U251 results reiterate our 
GBM data that targeting LRRC8A can be combined with existing 
chemotherapies.
Our understanding of GBM biology and pathophysiology 
continues to evolve due to advances in the fields of GBM genetics, 
epigenetics, and proteomics (64–66). As already mentioned, 
ion channels have been linked to many aspects of tumor 
pathophysiology and, therefore, receive increasing attention as 
potential biomarkers and/or therapeutic targets (10, 67, 68). 
GBM proliferation, migration, and invasion are dependent on 
expression and activity of several types of K+, Ca2+, non-selective 
cation, and Cl− channels (11, 30, 69–71). Among Cl− channels, 
ClC-2, -3, and -5, and chloride intracellular channels CLIC-1 
and CLIC-4 have been implicated in GBM  cell migration or 
associated with negative clinical outcomes (72, 73). Here, we 
add the pore-forming subunit of VRAC, LRRC8A, to the list of 
ion channel proteins potentially responsible for the aggressive 
nature of GBM. Importantly, we tested pathological relevance 
of the LRRC8A-containing VRAC in the primary GBM cells, in 
order to avoid limitations associated with using over-passaged 
glioma cell lines.
In the context of development of new treatment modalities, 
our present findings can be summarized as follows: (a)  com-
pared with TMZ and carmustine, the LRRC8A knockdown 
was twice as effective in reducing GBM cell numbers (20–25 vs. 
50–60% for chemotherapeutic agents and siRNA, respectively). 
(b) The combinatory treatment was three times more effective 
in reducing cell numbers, when compared with TMZ or car-
mustine alone (the combined toxicity reached 65–80% levels). 
Due to the diverse nature of GBM, our work will need to be 
further corroborated in additional GBM cell lines and in animal 
GBM models. These limitations notwithstanding, the LRRC8A-
containing VRAC appears to represent a new target for the 
treatment of GBM, alone or in combination with the current 
standard-of-care.
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eThics sTaTeMenT
Primary glioblastoma cells, which had been characterized in our 
prior work, were prepared from a surgical GBM tissue sample 
as previously described (30). The specimen was obtained under 
the protocol approved by the Albany Medical Center Institutional 
Review Board, with written patient consent. The GBM origin of 
tissue was histologically confirmed by a pathologist at the time 
of resection.
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FigUre s1 | Effects of the vehicle agent dimethyl sulfoxide (DMSO) on 
proliferation of glioblastoma (GBM) cells. GBM cells were grown in the presence 
of indicated concentrations of DMSO, and their relative proliferation rates were 
determined 48 h after addition of the tested agent with an MTT assay. The data 
are the mean values ± SE of four independent experiments. *p<0.05 vs. control 
cells grown in the absence of DMSO.
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